clinical trial · NCT04696731
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Advanced/Metastatic Clear Cell Renal Cell CarcinomaALLO-316ALLO-647FludarabineCyclophosphamide
brief summary
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.
started
Feb 24, 2021
primary completion
Oct 1, 2025
completion
Dec 1, 2025
last updated
Sep 25, 2025
official title
A Phase 1A/1B Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 With Cyclophosphamide/Fludarabine Lymphodepletion Alone or Including ALLO-647 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol